Participant flow

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma · Source last updated 2020-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   busulfan: IV busulfan 0.8 mg/kg every 6 hours x 16 doses cyclophosphamide: IV cyclophosphamide 60 mg/kg over 4 hours x 2 days autologous hematopoietic stem cell transplantation: infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0

   id

   FG000

   title

   Busulfan Treatment

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Withdrawal by Subject

   2. reasons

      1. group Id

         FG000

         num Subjects

         11

      type

      Insurance denied participation

   3. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      ineligible

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         71

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         57

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         14

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice